GLP-1 Pathway Nutritional Modulators

1 Butyrate and SCFA Supplementation

CautionSpeculation: Butyrate Supplementation to Enhance Endogenous GLP-1 Secretion

Certainty: 0.30. (Established SCFA→GLP-1 mechanism; ME/CFS dysbiosis with reduced butyrate producers replicated across some cohorts; supplement safety established; zero ME/CFS GLP-1 data.)

Short-chain fatty acids (butyrate, propionate, acetate) produced by gut microbiota are the primary endogenous stimulus for GLP-1 secretion from L cells, acting through FFAR2/FFAR3 (GPR43/GPR41) receptors. SCFAs also directly enhance vagal afferent sensitivity to GLP-1. ME/CFS patients have reduced SCFA-producing bacteria (Faecalibacterium, Roseburia) in some studies. Supplementing butyrate (as tributyrin or sodium butyrate) could restore endogenous GLP-1 secretion. This is an OTC, oral, cheap nutritional route to GLP-1 pathway modulation.

Falsifiable prediction. 4 weeks of tributyrin 2g/day increases postprandial GLP-1 AUC by β‰₯30% in ME/CFS vs placebo. GLP-1 increase correlates with reduction in fatigue score (VAS).

Limitations. Not all ME/CFS microbiome cohorts show reduced SCFAs. Effect may be small and dose-dependent. Gut tolerability may be an issue for butyrate at effective doses.

2 Berberine

CautionSpeculation: Berberine as Dual GLP-1 Secretagogue and AMPK-Metabolic Modulator

Certainty: 0.25. (GLP-1 secretagogue activity established in T2D; AMPK activation documented; some small ME/CFS trial data β€” mixed results, underpowered; OTC; used informally by ME/CFS patients.)

Berberine activates AMPK, improves mitochondrial function, stimulates GLP-1 secretion (via sweet taste receptors and TGR5 bile acid receptors), and improves glucose metabolism. It is oral, cheap, OTC. However, berberine has poor oral bioavailability (~5%), variable GLP-1 effects across studies, and can cause GI side effects. Some ME/CFS patients use it informally with mixed reports. Whether berberine’s GLP-1 effect is substantial enough to be clinically meaningful, or whether it acts primarily through AMPK-independent mechanisms, is unresolved.

Falsifiable prediction. Berberine 500mg TID Γ— 8 weeks increases postprandial GLP-1 AUC by β‰₯15% and reduces CRP by β‰₯0.5 mg/L in ME/CFS. GLP-1 change does NOT correlate with symptom improvement (suggesting AMPK-mediated effects dominate over GLP-1).

Limitations. Poor bioavailability limits effect size. GI side effects common. Variable response across ME/CFS patients. No dose-response data in ME/CFS.

3 Taurine

CautionSpeculation: Taurine as GLP-1 Secretagogue and Mitochondrial Modulator

Certainty: 0.25. (GLP-1 secretagogue activity established in vitro and in vivo; safety excellent (500mg–3g/day); taurine levels reported reduced in some ME/CFS metabolomics studies.)

Taurine stimulates GLP-1 secretion from L cells via TAS1R2/TAS1R3 sweet taste receptors and calcium-dependent exocytosis. It also improves mitochondrial function, reduces ER stress, and enhances insulin sensitivity β€” all mechanisms relevant to ME/CFS energy metabolism dysfunction. Taurine levels are reduced in ME/CFS in some metabolomics studies. Taurine supplementation is safe, cheap, and OTC.

Falsifiable prediction. Taurine 3g/day Γ— 4 weeks increases fasting and postprandial GLP-1 by β‰₯20% and improves DSQ-PEM score by β‰₯15% vs placebo.

Limitations. ME/CFS taurine data limited and mixed. Effect size likely small. GLP-1 secretagogue effect may be insufficient alone; combination with other strategies likely needed.